Univ.-Prof. Dipl.-Ing. Dr. Manfred Ogris
Summer term 2026
321014 VO Anatomie und Physiologie - B8
321026 VU Pharmazeutisches Imaging - B13 - (5 Kurse)
321031 PR Biochemische und vertiefende pharmazeutisch-chemische Arbeitstechniken - B17 - (6 Kurse)
323007 UE Experimental Methods in Drug Discovery und Preclinical Drug Development - MPS6 - (2 Courses)
Winter term 2025
321002 VO Steop Biologie für PharmazeutInnen - B2
321026 VU Pharmazeutisches Imaging - B13 - (4 Kurse)
321031 PR Biochemische und vertiefende pharmazeutisch-chemische Arbeitstechniken - B17 - (5 Kurse)
321126 VU Pharmazeutisches Imaging - B13 - Zusatzkurse - (2 Kurse)
323005 VO Preclinical Drug Development - MPS4
Summer term 2025
321014 VO Anatomie und Physiologie - B8
321026 VU Pharmazeutisches Imaging - B13 - (5 Kurse)
321031 PR Biochemische und vertiefende pharmazeutisch-chemische Arbeitstechniken - B17 - (6 Kurse)
321126 VU Pharmazeutisches Imaging - B13 - Zusatzkurse - (2 Kurse)
323007 UE Experimental Methods in Drug Discovery und Preclinical Drug Development - MPS6 - (2 Courses)
Shir A, Levitzki A, Wagner E, Klein S, Ogris M. Nucleic Acid-Based Therapeutics for Glioblastoma. Anti-Cancer Agents in Medicinal Chemistry. 2011 Oct;11(8):693-699.
Ogris M, Wagner E. To Be Targeted: Is the Magic Bullet Concept a Viable Option for Synthetic Nucleic Acid Therapeutics? Human Gene Therapy. 2011 Jul;22(7):799-807. doi: 10.1089/hum.2011.065
Nie Y, Schaffert D, Roedl W, Ogris M, Wagner E, Guenther M. Dual-targeted polyplexes: One step towards a synthetic virus for cancer gene therapy. Journal of Controlled Release. 2011 May 30;152(1):127-134. doi: 10.1016/j.jconrel.2011.02.028
Dussmann P, Pagel JI, Vogel S, Magnusson T, Zimmermann R, Wagner E et al. Live in vivo imaging of Egr-1 promoter activity during neonatal development, liver regeneration and wound healing. BMC Developmental Biology. 2011 May 20;11:28. doi: 10.1186/1471-213X-11-28
Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability-A step closer from promising technology to application. Journal of Controlled Release. 2011 May 10;151(3):246-255. doi: 10.1016/j.jconrel.2011.01.003
Klutz K, Schaffert D, Willhauck MJ, Gruenwald GK, Haase R, Wunderlich N et al. Epidermal Growth Factor Receptor-targeted I-131-therapy of Liver Cancer Following Systemic Delivery of the Sodium Iodide Symporter Gene. Molecular Therapy. 2011 Apr;19(4):676-685. doi: 10.1038/mt.2010.296
Schaffert D, Kiss M, Roedl W, Shir A, Levitzki A, Ogris M et al. Poly(I: C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier. Pharmaceutical Research. 2011 Apr;28(4):731-741. doi: 10.1007/s11095-010-0225-4
Shir A, Ogris M, Roedl W, Wagner E, Levitzki A. EGFR-Homing dsRNA Activates Cancer-Targeted Immune Response and Eliminates Disseminated EGFR-Overexpressing Tumors in Mice. Clinical Cancer Research. 2011 Mar 1;17(5):1033-1043. doi: 10.1158/1078-0432.CCR-10-1140
Stahnke S, Lux K, Uhrig S, Kreppel F, Hoesel M, Coutelle O et al. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology. 2011 Jan 5;409(1):77-83. doi: 10.1016/j.virol.2010.09.025
Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. The establishment of an up-scaled micro-mixer method allows the standardized and reproducible preparation of well-defined plasmid/LPEI polyplexes. European Journal of Pharmaceutics and Biopharmaceutics. 2011 Jan;77(1):182-185. doi: 10.1016/j.ejpb.2010.11.012
Magnusson T, Haase R, Schleef M, Wagner E, Ogris M. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations. Journal of Gene Medicine. 2011;13(7-8):382-391. doi: 10.1002/jgm.1585
Terziyska N, Farkasova K, Wagner E, Ogris M, Jeremias I. In Vivo Imaging In the Individualized Mouse Model of Acute Lymphoblastic Leukemia Enables Highly Sensitive and Continuous Follow up of Patient-Derived Xenografts. Blood. 2010 Nov 19;116(21):1336-1336.
Rupprecht S, Hagedorn C, Seruggia D, Magnusson T, Wagner E, Ogris M et al. Controlled removal of a nonviral episomal vector from transfected cells. Gene. 2010 Oct 15;466(1-2):36-42. doi: 10.1016/j.gene.2010.07.001
Gruenwald GK, Klutz K, Willhauck MJ, Wunderlich N, Senekowitsch-Schmidtke R, Ogris M et al. An alpha-Fetoprotein Promoter Driven, Conditionally Replicating Adenovirus that Expresses the Sodium Iodide Symporter (NIS) for Radiovirotherapy of HCC. Human Gene Therapy. 2010 Sept;21(9):1184-1184.
Espenlaub S, Corjon S, Engler T, Fella C, Ogris M, Wagner E et al. Analysis of Intracellular Particle Trafficking and Bioresponsive Bonds for Ad Vector Shielding by Capsomer-Specific Fluorescent Labeling. Human Gene Therapy. 2010 Sept;21(9):1179-1179.
Espenlaub S, Corjon S, Engler T, Fella C, Ogris M, Wagner E et al. Capsomer-Specific Fluorescent Labeling of Adenoviral Vector Particles Allows for Detailed Analysis of Intracellular Particle Trafficking and the Performance of Bioresponsive Bonds for Vector Capsid Modifications. Human Gene Therapy. 2010 Sept;21(9):1155-1167. doi: 10.1089/hum.2009.171
Vetter A, Virdi KS, Espenlaub S, Roedl W, Wagner E, Holm PS et al. Chemical Modification of the Adenovirus Capsid for Enhanced Viral Uptake into Target Cells. Human Gene Therapy. 2010 Sept;21(9):1193-1193.
Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. Development of a Stable Lyophilized Formulation for LPEI Polyplexes. Human Gene Therapy. 2010 Sept;21(9):1189-1189.
Koenig FM, Ruthardt N, Wagner E, Ogris M, Braeuchle C. EGF Receptor Targeting of Polyplexes with the Short Artificial Peptide GE11 Studied by Live Cell Imaging. Human Gene Therapy. 2010 Sept;21(9):1180-1181.
Haase R, Magnusson T, Wagner E, Ogris M. Generation of the Novel, Synthetic Hybrid SCE-Promoter for Gene-Therapeutical Applications. Human Gene Therapy. 2010 Sept;21(9):1190-1190.
Multimodal optical tomography to study pharmacokinetics and pharmacodynamics in cancer models
Ogris, M. (Speaker)
14 Jun 2024
Activity: Talks and presentations › Talk or oral contribution › Science to Science
Polycation based mRNA delivery: bottlenecks and solutions
Ogris, M. (Speaker)
21 May 2024 → 23 May 2024
Activity: Talks and presentations › Talk or oral contribution › Science to Science
Wie unser Immunsystem uns vor Tumoren schützt
Ogris, M. (Speaker)
5 Mar 2024
Activity: Talks and presentations › Talk or oral contribution › Science to Public
Water-soluble NHC stabilized Gold Nanoparticles
Reithofer, M. (Speaker), Chin, J. M. (Contributor), Young, A. J. (Speaker), Sami, H. (Contributor), Eisen, C. (Contributor), Rubio, G. (Contributor), Tepe, N. (Contributor), Hofmann, T. (Contributor), Ogris, M. (Contributor) & Keppler, B. (Contributor)
11 Aug 2019
Activity: Talks and presentations › Talk or oral contribution › Science to Science
Department of Pharmaceutical Sciences
Josef-Holaubek-Platz 2 (UZA II)
1090 Wien
Room: 2D450
T: +43-1-4277-55551